+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market by Vaccine Type (Combination Vaccine, Monovalent Vaccine), Dosage Form (Liquid For Injection, Lyophilized Powder For Injection), Administration Route, End User, Animal Age Group, Sales Channel - Global Forecast 2025-2030- Product Image
Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market by Vaccine Type (Combination Vaccine, Monovalent Vaccine), Dosage Form (Liquid For Injection, Lyophilized Powder For Injection), Administration Route, End User, Animal Age Group, Sales Channel - Global Forecast 2025-2030- Product Image
New

Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market by Vaccine Type (Combination Vaccine, Monovalent Vaccine), Dosage Form (Liquid For Injection, Lyophilized Powder For Injection), Administration Route, End User, Animal Age Group, Sales Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6147965
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Comprehensive Primer on Porcine Circovirus and Mycoplasma Hyopneumoniae Vaccine Market Dynamics and Core Drivers Shaping Industry Potential

Porcine circovirus type 2 and Mycoplasma hyopneumoniae co-infections pose significant challenges due to synergistic pathogenicity affecting swine production across the globe. As herd health management becomes increasingly complex, producers and veterinarians are turning to combined vaccine formulations that deliver broad-spectrum protection against both PCV and mycoplasmal pneumonia. This shift toward integrated immunization strategies underscores the need for a centralized resource that synthesizes scientific, regulatory, and commercial developments.

Against this backdrop, this executive summary offers a comprehensive primer on the critical factors shaping adoption and innovation in the porcine circovirus-myco hybrid vaccine space. Through an in-depth exploration of market drivers, regulatory influences, and stakeholder behavior, readers will gain clarity on the emerging pathways to maximizing vaccine efficacy, ensuring supply chain resilience, and optimizing cost structures. By laying this foundation, the introduction sets the stage for a deep dive into the transformative forces redefining the landscape of swine health solutions.

Revolutionary Technological, Regulatory, and Stakeholder Shifts Rapidly Reshaping the Porcine Vaccine Landscape

The evolution of the porcine circovirus-myco vaccine market is being propelled by multi-dimensional shifts in technology, regulation, and stakeholder expectations. Advances in antigen delivery platforms have enabled stable combination vaccines that reduce handling complexity while enhancing immunogenic synergy. Smartphone-enabled cold chain monitoring and blockchain-anchored traceability frameworks are now elevating supply chain transparency, ensuring product integrity from production through administration. Concurrently, regulatory agencies worldwide are streamlining approval pathways for novel adjuvant systems, opening doors for next-generation formulations that promise extended duration of immunity.

Meanwhile, producers are increasingly demanding tailored vaccine protocols that align with specific production systems and regional disease pressures. Digital farming platforms are capturing on-farm health metrics, enabling data-driven vaccination schedules that optimize timing and dosage. Collectively, these transformations are not only redefining product development roadmaps but also reshaping commercial engagement models, as manufacturers pivot from transactional sales toward integrated service offerings that drive measurable herd health outcomes.

Assessing the Full-Scale Repercussions of United States 2025 Tariff Measures on Vaccine Production and Supply Network Resilience

The introduction of broad-based tariffs on vaccine inputs, raw materials, and biologics intermediates in 2025 has reverberated across every link of the porcine vaccine supply chain. Manufacturers are grappling with elevated costs for recombinant vectors, adjuvant components, and specialized packaging, requiring them to reexamine supplier networks and sourcing strategies. Increased import duties have also triggered delays at key logistics hubs, complicating cold chain requirements and risking potency losses during transit.

In response, leading developers have accelerated investments in domestic production capabilities and localized fill-finish operations to mitigate tariff exposure. Strategic collaborations with regional contract manufacturing organizations have become essential to preserving margin profiles. At the same time, some suppliers are renegotiating long-term purchase agreements to incorporate tariff escalation clauses, thereby shielding end users from unpredictable cost spikes. This recalibration underscores the importance of agile supply chain design in maintaining both affordability and product integrity.

Deep Dive into Vaccine Type, Dosage Form, Administration Route, End User, Age Group, and Sales Channel Segmentation Influencing Developments

Insight into vaccine segmentation reveals that combination formulations are steadily becoming the cornerstone of integrated herd health protocols, reducing the frequency of interventions while broadening protective coverage. Yet monovalent options continue to play a pivotal role in targeted immunization strategies that cater to herds with specific disease prevalence or biosecurity requirements. The distinction between liquid and lyophilized dosage forms further underscores the industry’s need for flexibility: liquid injections in multidose vials are optimized for high-volume operations, whereas single-dose options provide aseptic assurance and minimal waste. Lyophilized powder presentations, supported by reconstitution kits, offer enhanced stability during transport and extended shelf life under variable cold chain conditions.

Administration routes also inform the optimization of immune response and ease of deployment, as intramuscular injections are favored for robust systemic immunity, while subcutaneous applications support rapid field administration with minimal stress to animals. End-user dynamics illustrate that animal farms with commercial hog operations demand scalable solutions, research laboratories focus on high-precision formulations, and veterinary clinics prioritize client convenience and safety. Furthermore, age group categorization from finishers and growers to sows and weaners directs dosage schedules and adjuvant selection, ensuring age-appropriate immunogenicity. Finally, sales channel performance is driven by direct engagements for high-value accounts, distribution partnerships that extend geographic reach, and the emergence of online platforms offering streamlined procurement and real-time order tracking.

Comparative Analysis of Americas Leadership, EMEA Regulatory Collaboration, and Asia-Pacific Expansion Trends Driving Vaccine Adoption

Regional dynamics underscore the Americas’ leadership in both innovation and commercial deployment, supported by advanced cold chain logistics, robust research infrastructure, and a high degree of producer sophistication. North America, in particular, showcases early adoption of combination vaccines and digital supply solutions, while Latin American producers are rapidly scaling immunization efforts to combat endemic strains. Across Europe, Middle East & Africa, regulatory harmonization efforts and veterinary service networks are strengthening market entry pathways, catalyzing partnerships between multinational developers and local distributors to optimize reach.

Meanwhile, the Asia-Pacific region stands at the forefront of growth thanks to expanding pork production, government-backed herd health programs, and rising investments in pharmaceutical manufacturing. China and Southeast Asian markets are embracing new platforms for vaccine delivery, while Australia and New Zealand continue to refine biosecurity measures through rigorous livestock monitoring. These regional variations in regulatory frameworks, disease prevalence, and logistical capacity illustrate the importance of tailored market entry strategies and highlight opportunities for localized innovation.

Strategic R&D, Partnership-Driven Growth, and Digital Service Integration Defining Leading Porcine Vaccine Providers’ Competitive Edge

The competitive landscape is defined by a quartet of influential innovators that continuously invest in research and development to maintain pipeline vitality and regulatory compliance. These organizations leverage proprietary adjuvant technologies and advanced antigen expression systems to differentiate their combination vaccine offerings. Strategic alliances with academic institutions and contract manufacturing partners further accelerate time-to-market for incremental formulation upgrades.

Smaller, specialized biotechnology firms are carving out niche positions by focusing on novel adjuvant chemistries and targeted delivery devices designed to enhance mucosal immunity. At the same time, traditional animal health conglomerates are integrating digital service platforms into their commercial models, offering herd health monitoring algorithms and remote veterinary support. Collectively, this blend of incumbents and agile entrants is fostering a dynamic environment where both scale and specialization drive competitive advantage.

Innovative Localization, Data-Driven Service Models, and Pilot-Scale Modular Production Strategies for Future-Proofing

Industry leaders should prioritize the establishment of regional fill-finish hubs to circumvent tariff pressures and logistical bottlenecks. By localizing critical production stages, organizations can maintain product integrity while stabilizing cost structures. In parallel, adopting modular manufacturing technologies will improve responsiveness to emerging strain variations and support small-batch runs for clinical trials or pilot programs.

Embracing data-driven vaccination schedules informed by on-farm analytics platforms will enable a shift toward outcome-based service agreements, aligning product fees with measurable improvements in herd health metrics. Furthermore, forging joint ventures with regional distributors and veterinary networks can amplify market penetration while sharing commercial risks. Finally, accelerating the development of single-use reconstitution systems and user-friendly delivery devices will enhance field usability and client satisfaction, cementing long-term adoption across diverse production systems.

Robust Mixed-Methods Research Employing Expert Interviews, Regulatory Filings Analysis, and Quantitative Data Triangulation

This research integrates a rigorous mixed-methods approach combining primary stakeholder interviews, secondary literature review, and quantitative data triangulation. Primary insights were gathered through in-depth conversations with industry executives, veterinary experts, contract manufacturers, and procurement officers across major swine-producing regions. Secondary research synthesized information from regulatory filings, scientific publications, and trade association reports to ensure alignment with the latest policy and technological developments.

Quantitative analyses were conducted by cross-referencing production output data, tariff schedules, and distribution channel metrics from publicly available databases. Findings were validated through iterative reviews with a panel of independent subject matter experts to confirm methodological robustness and eliminate bias. This comprehensive framework delivers both the breadth and depth required for confident decision-making in a rapidly evolving market environment.

Synthesis of Strategic Imperatives and Pathways to Sustain Competitive Advantage in an Evolving Vaccine Ecosystem

The convergence of enhanced vaccine formulations, evolving regulatory standards, and strategic supply chain innovations underscores a pivotal moment for porcine herd health management. As tariff landscapes shift and disease pressures intensify, stakeholders must adapt by embracing agile manufacturing, data-centric service offerings, and regional partnerships. The insights presented here illuminate clear pathways for optimizing vaccine efficacy, streamlining distribution, and sustaining competitive advantage.

Moving forward, market participants who integrate these strategic imperatives will be best positioned to navigate uncertainty, capitalize on emerging growth corridors, and drive measurable improvements in production performance. This executive summary thus serves as both a roadmap and a catalyst for informed action in an increasingly interconnected global vaccine ecosystem.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Vaccine Type
    • Combination Vaccine
    • Monovalent Vaccine
  • Dosage Form
    • Liquid For Injection
      • Multidose Vial
      • Single Dose Vial
    • Lyophilized Powder For Injection
      • Reconstitution Kit
  • Administration Route
    • Intramuscular Injection
    • Subcutaneous Injection
  • End User
    • Animal Farms
    • Research Laboratories
    • Veterinary Clinics
  • Animal Age Group
    • Finishers
    • Grower Pigs
    • Sows
    • Weaner Pigs
  • Sales Channel
    • Direct Sales
    • Distribution Partners
    • Online Channel
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Ceva Santé Animale S.A.
  • Boehringer Ingelheim International GmbH
  • Elanco Animal Health Incorporated
  • Hipra, S.A.
  • Phibro Animal Health Corporation
  • Wuhan Keqian Biology Co., Ltd.
  • Pharmgate Animal Health Private Limited
  • Indian Immunologicals Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of combination PCV-Mycoplasma hyopneumoniae vaccines in swine herds to streamline immunization schedules and reduce handling stress
5.2. Research on next-generation adjuvant systems to boost immunogenicity of PCV-Mycoplasma hyopneumoniae vaccines in young piglets
5.3. Regulatory harmonization initiatives in major swine-producing regions streamlining approval processes for combination vaccines
5.4. Integration of real-time monitoring and data analytics to assess vaccine efficacy against PCV and mycoplasma in commercial herds
5.5. Rising interest in needle-free vaccine delivery technologies to improve compliance and biosecurity in swine operations
5.6. Expansion of PCV-Mycoplasma hyopneumoniae vaccination programs in emerging markets driven by growing pork production and disease incidence
5.7. Public-private partnerships funding development of multivalent vaccines to address co-infections in intensive pig farming systems
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market, by Vaccine Type
8.1. Introduction
8.2. Combination Vaccine
8.3. Monovalent Vaccine
9. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market, by Dosage Form
9.1. Introduction
9.2. Liquid For Injection
9.2.1. Multidose Vial
9.2.2. Single Dose Vial
9.3. Lyophilized Powder For Injection
9.3.1. Reconstitution Kit
10. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market, by Administration Route
10.1. Introduction
10.2. Intramuscular Injection
10.3. Subcutaneous Injection
11. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market, by End User
11.1. Introduction
11.2. Animal Farms
11.3. Research Laboratories
11.4. Veterinary Clinics
12. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market, by Animal Age Group
12.1. Introduction
12.2. Finishers
12.3. Grower Pigs
12.4. Sows
12.5. Weaner Pigs
13. Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market, by Sales Channel
13.1. Introduction
13.2. Direct Sales
13.3. Distribution Partners
13.4. Online Channel
14. Americas Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Zoetis Inc.
17.3.2. Merck & Co., Inc.
17.3.3. Ceva Santé Animale S.A.
17.3.4. Boehringer Ingelheim International GmbH
17.3.5. Elanco Animal Health Incorporated
17.3.6. Hipra, S.A.
17.3.7. Phibro Animal Health Corporation
17.3.8. Wuhan Keqian Biology Co., Ltd.
17.3.9. Pharmgate Animal Health Private Limited
17.3.10. Indian Immunologicals Limited
18. Research AI19. Research Statistics20. Research Contacts21. Research Articles22. Appendix
List of Figures
FIGURE 1. PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET: RESEARCHAI
FIGURE 28. PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET: RESEARCHSTATISTICS
FIGURE 29. PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET: RESEARCHCONTACTS
FIGURE 30. PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY MULTIDOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY MULTIDOSE VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY RECONSTITUTION KIT, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY RECONSTITUTION KIT, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY FINISHERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY FINISHERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY GROWER PIGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY GROWER PIGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SOWS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SOWS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY WEANER PIGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY WEANER PIGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DISTRIBUTION PARTNERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DISTRIBUTION PARTNERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 99. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 100. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 101. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 102. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 103. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 104. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 105. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 106. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 107. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 108. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 109. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 112. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 113. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. CANADA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 116. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 117. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 118. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 119. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 120. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 124. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 125. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 128. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 129. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. MEXICO PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 198. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 199. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 200. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 201. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 202. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 203. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 204. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 205. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 206. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 207. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. GERMANY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 214. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 215. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 216. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 217. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 218. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 219. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 220. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 221. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 222. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 223. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 224. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 225. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 226. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 227. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. FRANCE PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LYOPHILIZED POWDER FOR INJECTION, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY ANIMAL AGE GROUP, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. ITALY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
TABLE 246. ITALY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
TABLE 247. ITALY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. ITALY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. ITALY PORCINE CIRCOVIRUS-MYCOPLASMA HYOPNEUMONIAE VACCINE MARKET SIZE, BY LIQUID FOR INJECTION, 2

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Porcine Circovirus-Mycoplasma Hyopneumoniae Vaccine Market report include:
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Ceva Santé Animale S.A.
  • Boehringer Ingelheim International GmbH
  • Elanco Animal Health Incorporated
  • Hipra, S.A.
  • Phibro Animal Health Corporation
  • Wuhan Keqian Biology Co., Ltd.
  • Pharmgate Animal Health Private Limited
  • Indian Immunologicals Limited

Related Topics

Related Reports

Global Porcine Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Porcine Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 120 Pages
  • Global
From
Porcine Vaccine Market Report 2025 - Product Image

Porcine Vaccine Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Swine Vaccines - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Swine Vaccines - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 120 Pages
  • Global
From
Swine Vaccines - Global Strategic Business Report - Product Image

Swine Vaccines - Global Strategic Business Report

  • Report
  • 398 Pages
  • Global
From
Veterinary Vaccines Market Report 2025 - Product Image

Veterinary Vaccines Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.